InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.740

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$353 Appendix 4G - Corporate Governance Statement 28 Aug 2017 9:23AM $0.935 $0.740 fallen by 20.86%
$353 Annual report and full year financial results 28 Aug 2017 9:19AM $0.935 $0.740 fallen by 20.86%
$353 Starpharma to present at Finance News Network Investor Event 24 Aug 2017 12:30AM $0.910 $0.740 fallen by 18.68%
$353 Appendix 3B 21 Aug 2017 4:40PM $0.925 $0.740 fallen by 20%
$353 Starpharma and Monash awarded STEM Business Fellowships 9 Aug 2017 9:54AM $0.835 $0.740 fallen by 11.38%
$353 Successful VivaGel Phase 3 results and NDA planned for rBV 7 Aug 2017 9:20AM $0.760 $0.740 fallen by 2.63%
$353 Appendix 4C - Quarterly Cashflow Report 19 Jul 2017 9:35AM $0.745 $0.740 fallen by 0.67%
$353 Shareholder Update July 2017 4 Jul 2017 1:43PM $0.730 $0.740 risen by 1.37%
$353 VivaGel BV phase 3 results timing and commercialisation 4 Jul 2017 9:45AM $0.730 $0.740 risen by 1.37%
$353 Appendix 3B 14 Jun 2017 3:21PM $0.745 $0.740 fallen by 0.67%
$353 Sale of Agrochemicals Business Investor Presentation 14 Jun 2017 10:34AM $0.730 $0.740 risen by 1.37%
$353 Starpharma sells Agrochemicals business to Agrium for $35M 14 Jun 2017 8:32AM $0.700 $0.740 risen by 5.71%
$353 DEP irinotecan outperforms irinotecan in cancer models 6 Jun 2017 9:34AM $0.680 $0.740 risen by 8.82%
$353 Starpharma receives DEP milestone from AstraZeneca 2 Jun 2017 9:40AM $0.665 $0.740 risen by 11.28%
$353 Appendix 4C - Quarterly Cashflow Report 28 Apr 2017 9:22AM $0.740 $0.740 fallen by 0%
$353 AstraZeneca DEP candidate advance triggers milestone to SPL 20 Apr 2017 9:19AM $0.675 $0.740 risen by 9.63%
$353 Ansell launches VivaGel condom in Canada 12 Apr 2017 9:03AM $0.665 $0.740 risen by 11.28%
$353 VivaGel BV phase 3 trials for prevention of BV completed 30 Mar 2017 9:37AM $0.695 $0.740 risen by 6.47%
$353 Interim Report and Half-Year Financial Results 27 Feb 2017 9:45AM $0.725 $0.740 risen by 2.07%
$353 Appendix 4C - Quarterly Cashflow Report 31 Jan 2017 9:45AM $0.780 $0.740 fallen by 5.13%
$353 Appendix 3B 25 Jan 2017 3:36PM $0.825 $0.740 fallen by 10.30%
$353 Shareholder Update January 2017 19 Jan 2017 9:30AM $0.855 $0.740 fallen by 13.45%
$353 VivaGel BV granted QIDP and Fast Track designation by US FDA 12 Jan 2017 9:19AM $0.735 $0.740 risen by 0.68%
$353 Starpharma receives $3.5M R&D tax incentive refund 22 Dec 2016 9:25AM $0.685 $0.740 risen by 8.03%
$353 Change in Director's Interest Notice - J Fairley 5 Dec 2016 4:33PM $0.740 $0.740 fallen by 0%

551 - 575 of 885 results

Page 23 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.